Iron deficiency is prevalent in one-third of cancer patients and rises to 90% during chemotherapy. The importance of targeted nutritional correction with iron is emphasized in the preoperative and chemotherapy phases.

OBJECTIVE

To assess the impact of iron citrate «Sintezit» on anemic mitochondrial disorders and chemotherapy tolerance in colorectal cancer and lymphoproliferative diseases.

MATERIALS AND METHODS

Ninety-nine patients receiving chemotherapy were divided into three groups: the first group — 38 patients with stage II colorectal cancer, the second group — 42 patients with lymphoproliferative diseases, 19 patients in the third group — control with oncopathology without iron citrate therapy. Iron citrate «Syntezit» was administered orally, 10 drops under the tongue once a day throughout the course of chemotherapy. Biochemical and clinical blood parameters, indicators of lipid peroxidation (LPO), antioxidant defense enzymes (ADE), mitochondrial enzymes, ECG, echocardiography, pulse oximetry were assessed in dynamics. The clinical and overall condition were evaluated using a questionnaire.

RESULTS

Both groups showed improvement in overall well-being, alleviation of asthenia, increased physical endurance and appetite, enhanced sleep, absence of dyspepsia, and mitigation of tachycardia and shortness of breath. As a result of iron citrate therapy, 99.7% of patients experienced an increase in hematocrit, hemoglobin, iron, ferritin, transferrin, erythropoietin, and mitochondrial enzymes. Reduction in POL, elevation in ADE, normalization of hemorheological parameters, and improved myocardial contractility with increased ejection fraction were also noted.

CONCLUSION

Iron citrate «Sintezit» contributes to enhanced mitochondrial function, increased arterial blood oxygen saturation, ATP production, and positive effects on biochemical and metabolic parameters.